anti cd3 immunotoxin a dmdt390 bisfvucht1

Drug Overview

The medication known as anti cd3 immunotoxin a dmdt390 bisfvucht1 (also identified by the proposed marketing name Resimmune®) is a first-in-class, investigational “smart toxin” designed to treat T-cell malignancies and autoimmune diseases. It is a bivalent recombinant fusion protein that acts as a targeted biological weapon.

Developed primarily by Angimmune LLC and researchers at the National Institutes of Health (NIH), Resimmune is engineered to seek out cells displaying the CD3 protein—a hallmark of mature T-cells—and deliver a lethal bacterial toxin payload directly into them. This makes it particularly effective for treating cancers that arise from T-cells, such as cutaneous T-cell lymphoma (CTCL).

• Generic Name: A-dmDT390-bisFv(UCHT1).
• Brand Name: Resimmune® (Investigational).
• Drug Class: Recombinant Immunotoxin / Protein Synthesis Inhibitor.
• Target: CD3\varepsilon (T-cell receptor complex).
• Payload: Truncated Diphtheria Toxin (DT390).
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of March 2026, Resimmune is not FDA-approved. It holds Orphan Drug Designation for the treatment of Cutaneous T-Cell Lymphoma (CTCL). Clinical development has progressed through Phase I/II trials, and it has also been explored as an immunomodulator in metastatic melanoma.

What Is It and How Does It Work? (Mechanism of Action)

The CD3 Targeting Arm

The drug uses two “single-chain variable fragments” (bisFv) derived from the UCHT1 antibody. These arms specifically recognize the CD3\varepsilon subunit of the T-cell receptor. Because it is bivalent (having two binding sites), Resimmune binds much more tightly to the target than earlier monovalent versions.

Molecular Level Mechanisms

1. Selective Binding: After infusion, Resimmune binds to the CD3 receptor on both malignant and normal T-lymphocytes.
2. Internalization: The T-cell pulls the drug-receptor complex inside via endocytosis.
3. Toxin Translocation: Inside the cell, the translocation domain of the diphtheria toxin (DT) allows the catalytic “A chain” to escape the endosome and enter the cell’s main interior (cytosol).
4. Ribosomal Shutdown: The DT moiety catalyzes the ADP-ribosylation of Elongation Factor 2 (EF-2).
5. Irreversible Protein Inhibition: By disabling EF-2, the toxin permanently stops the cell from building new proteins.
6. Apoptosis: Within hours, the cell realizes it cannot function and commits “programmed suicide” (apoptosis).
7. Immunomodulation: Interestingly, Resimmune transiently depletes nearly all T-cells. When the body regenerates these cells (homeostatic proliferation), it often creates a “reset” immune environment that may better recognize and attack remaining cancer cells.

FDA Approved Clinical Indications

There are currently no FDA-approved clinical indications for Resimmune.

It is strictly available through participation in clinical trials (such as NCT00611208 and NCT02943642). It has been studied for:

• Cutaneous T-Cell Lymphoma (CTCL): Including Mycosis Fungoides and Sezary Syndrome. In early trials, a specific subgroup (Stage IB-IIB) showed an 89% response rate.
• Metastatic Melanoma: Investigated in combination with radiation and Keytruda (Pembrolizumab) to act as an immune “primer.”
• T-Cell Driven Autoimmune Diseases: Potential applications in Multiple Sclerosis (MS) and Graft-versus-Host Disease (GvHD).

Dosage and Administration Protocols

Resimmune is administered as a short, intense “pulse” of therapy rather than a long-term regimen.

Clinical Efficacy and Research Results

Clinical data from 2009 through 2026 highlights the drug’s high potency in specific patient populations.

• CTCL Breakthrough: Phase I/II data identified a high-responder group with low tumor burden (mSWAT < 50) where the Complete Response (CR) rate was 50%. Some of these remissions have lasted over 72 months, which researchers suggest could represent clinical “cures.”
• Memory T-cell Induction: In melanoma trials, the drug was found to induce a 20-fold increase in CD8+ central memory T-cells, which are vital for long-term anti-tumor surveillance.
• Bivalent Advantage: The “bisFv” design makes the drug roughly 10 times more potent than the older, monovalent versions of anti-CD3 toxins.

Safety Profile and Side Effects

The primary safety challenge for Resimmune is the potential for the toxin to affect blood vessel linings.

Common Side Effects (>20%):

• Fever and Chills: Standard “hypersensitivity” reactions during the infusion.
• Transaminitis: Temporary elevation of liver enzymes (ALT/AST).
• Hypoalbuminemia: A drop in albumin levels in the blood.
• Peripheral Edema: Mild swelling in the hands or feet.

Serious Adverse Events:

• Vascular Leak Syndrome (VLS): A rare but serious condition where fluid leaks out of small blood vessels. Patients with pre-existing heart failure are at significantly higher risk.
• Viral Reactivation: Because the drug transiently depletes T-cells, there is a risk of EBV or CMV “waking up,” requiring monitoring.
• Immunogenicity: All patients eventually develop anti-diphtheria toxin antibodies after the first week, which usually prevents a second course of treatment from being effective.

Research Areas

In Stem Cell and Regenerative Medicine, Resimmune is used to study “Immune Niche Clearance.” Researchers are investigating its ability to “wipe the slate clean” of autoimmune T-cells before a patient receives a Stem Cell Transplant. The goal is to allow the new, healthy stem cells to regenerate a “naive” immune system that has no memory of the previous autoimmune or malignant behavior.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• Anti-DT Titer: Patients must have an anti-diphtheria toxin antibody level of < 20 \mug/ml; if the level is too high, the patient’s own immune system will neutralize the drug before it can kill the cancer.
• Baseline Albumin and Liver Panels: To monitor for VLS and liver stress.
• Echocardiogram (LVEF > 50%): Essential to ensure the heart can handle potential fluid shifts.

Precautions:

• Beta-Blocker Switch: Patients on beta-blockers must switch to other blood pressure meds 2–3 weeks before treatment to prevent heart rate issues during infusion.
• Step-up Monitoring: Frequent blood draws are required for the first 30 days to monitor the T-cell “re-population” process.

“Do’s and Don’ts” List:

• DO report any sudden weight gain or “puffiness” immediately; this can be an early sign of VLS.
• DO expect a short-term drop in your immune count; this is a sign the drug is hitting its target.
• DON’T ignore a high fever or “shaking chills” during the 15-minute infusion.
• DON’T plan for long-term maintenance; this is intended as a single, 4-day “hit” to the cancer.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Resimmune (A-dmDT390-bisFv(UCHT1)) is an investigational agent and is not approved by the US FDA. It is available only through participation in approved clinical trials. Always consult with a qualified hematologist-oncologist regarding currently available treatments and your eligibility for research.